DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 57.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 301,303 shares of the medical research company's stock after selling 399,586 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main owned approximately 0.17% of IQVIA worth $59,209,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Howard Capital Management Inc. grew its holdings in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after acquiring an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock valued at $1,068,000 after purchasing an additional 56 shares during the last quarter. Cypress Wealth Services LLC grew its stake in IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock valued at $244,000 after purchasing an additional 57 shares in the last quarter. Harbor Investment Advisory LLC increased its position in shares of IQVIA by 4.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock worth $253,000 after purchasing an additional 58 shares during the last quarter. Finally, Magnolia Capital Advisors LLC boosted its holdings in shares of IQVIA by 2.9% in the 4th quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock valued at $516,000 after buying an additional 74 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on IQV. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Citigroup cut their target price on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Mizuho lowered their price target on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Barclays cut their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday. Finally, HSBC lowered IQVIA from a "buy" rating to a "hold" rating and decreased their target price for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $231.71.
Check Out Our Latest Research Report on IQVIA
IQVIA Stock Performance
NYSE:IQV opened at $153.39 on Friday. The company has a market cap of $27.04 billion, a price-to-earnings ratio of 20.45, a PEG ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a fifty day moving average price of $164.60 and a 200-day moving average price of $189.07.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. During the same quarter in the prior year, the business posted $2.54 earnings per share. IQVIA's revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
